The Biotech Growth Trust (LON:BIOG) Stock Price Passes Below 200 Day Moving Average – Time to Sell?

The Biotech Growth Trust PLC (LON:BIOG)’s stock price passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of GBX 958.04 ($12.06) and traded as low as GBX 850.45 ($10.70). The Biotech Growth Trust shares last traded at GBX 852 ($10.72), with a volume of 48,347 shares traded.

The Biotech Growth Trust Trading Down 0.4 %

The company’s fifty day moving average is GBX 869.02 and its two-hundred day moving average is GBX 958.04. The company has a debt-to-equity ratio of 11.02, a quick ratio of 0.00 and a current ratio of 0.59. The company has a market cap of £243.41 million, a price-to-earnings ratio of 2.86 and a beta of 0.50.

The Biotech Growth Trust (LON:BIOG) last issued its quarterly earnings results on Wednesday, November 27th. The company reported GBX 0.20 ($0.00) earnings per share for the quarter. The Biotech Growth Trust had a net margin of 95.33% and a return on equity of 26.96%.

Insiders Place Their Bets

In related news, insider Nicola Shepherd acquired 1,000 shares of the stock in a transaction on Monday, January 13th. The shares were acquired at an average price of GBX 846 ($10.65) per share, for a total transaction of £8,460 ($10,648.21). Also, insider Hamish Baillie bought 3,000 shares of the firm’s stock in a transaction dated Wednesday, November 27th. The shares were acquired at an average price of GBX 931 ($11.72) per share, for a total transaction of £27,930 ($35,154.19). In the last 90 days, insiders have purchased 6,222 shares of company stock worth $5,659,584. Corporate insiders own 0.71% of the company’s stock.

The Biotech Growth Trust Company Profile

The Biotech Growth Trust seeks capital appreciation through investment in the worldwide biotechnology industry. In order to achieve its investment objective, the Company invests in a diversified portfolio of shares and related securities in biotechnology companies on a worldwide basis. Performance is measured against the NASDAQ Biotechnology Index (sterling adjusted).